T1	Participants 38 76	patients with advanced gastric cancer:
T2	Participants 289 530	patients with non-resectable gastric and gastro-oesophageal adenocarcinoma. Three hundred and sixty-nine patients with histological proof of adenocarcinoma, who had received no more than a single regimen of 5-fluorouracil-based chemotherapy,